BAKER BROS ADVISORS LP's Q1 2022 13F: 2 new positions, 3 exits
Form 13F-HR for the quarter ended Mar 31, 2022 · filed May 16, 2022 · 115 reported positions · accession 0001104659-22-061288
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | Incyte Corporation (INCY) | 12.1% | 16.6% | +4.5 pts | +2.54M sh | +8% |
| Increased | Horizon Therapeutics Public Ltd Co (HZNP) | 0.3% | 0.5% | +0.2 pts | +300K sh | +50% |
| Increased | 2seventy bio, Inc. (TSVT) | 0.1% | 0.2% | +0.1 pts | +1.23M sh | +148% |
| Reduced | ChemoCentryx, Inc. (CCXI) | 0.3% | 0.1% | −0.2 pts | −714K sh | −44% |
| Reduced | Legend Biotech Corporation (LEGN) | 0.6% | 0.4% | −0.1 pts | −480K sh | −19% |
| Increased | Replimune Group, Inc. (REPL) | 0.1% | 0.2% | +0.1 pts | +1.02M sh | +172% |
| Increased | Travere Therapeutics, Inc. (TVTX) | 0.4% | 0.5% | +0.1 pts | +631K sh | +24% |
| Increased | Affimed N.V. (AFMD) | 0.1% | 0.1% | +0.1 pts | +2.5M sh | +94% |
| Increased | Kodiak Sciences Inc. (KOD) | 6.1% | 0.7% | −5.4 pts | +1.25M sh | +9% |
| New | Vera Therapeutics, Inc. (VERA) | — | 0.0% | 0.0 pts | +333K sh | new |
| Increased | Verastem, Inc. (VSTM) | 0.2% | 0.2% | 0.0 pts | +5.5M sh | +26% |
| Increased | Biomea Fusion, Inc. (BMEA) | 0.0% | 0.0% | 0.0 pts | +1.03M sh | +196% |
| Increased | Aerovate Therapeutics, Inc. (AVTE) | 0.1% | 0.2% | +0.1 pts | +238K sh | +13% |
| Increased | HOOKIPA Pharma Inc. (HOOK) | 0.0% | 0.0% | 0.0 pts | +1.7M sh | +243% |
| Increased | Tricida, Inc. (TCDAQ) | 0.1% | 0.1% | 0.0 pts | +447K sh | +35% |
| Reduced | Opthea Limited (CYVNY) | 0.1% | 0.1% | 0.0 pts | −500K sh | −16% |
| Increased | Rhythm Pharmaceuticals, Inc. (RYTM) | 0.2% | 0.3% | +0.1 pts | +262K sh | +7% |
| Increased | Seagen Inc. (SGEN) | 35.5% | 39.0% | +3.5 pts | +18,902 sh | 0% |
| Exited | Albireo Pharma, Inc. (ALBO) | 0.0% | — | 0.0 pts | −105K sh | −100% |
| Exited | Gamida Cell Ltd. (GMDA) | 0.0% | — | 0.0 pts | −611K sh | −100% |
| New | Epizyme, Inc. (EPZM) | — | 0.0% | 0.0 pts | +1M sh | new |
| Exited | Evofem Biosciences, Inc. (EVFM) | 0.0% | — | 0.0 pts | −2.7M sh | −100% |
| Reduced | Kura Oncology, Inc. (KURA) | 0.0% | 0.0% | 0.0 pts | −29,700 sh | −10% |
| Increased | FibroGen, Inc. (FGEN) | 0.0% | 0.0% | 0.0 pts | +1,600 sh | 0% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 85.4% of the equity book
Changes in the top 10 this quarter: MDGL entered · MRTX left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Seagen Inc. (SGEN) | 35.5% | 39.0% | |
| 2 | Incyte Corporation (INCY) | 12.1% | 16.6% | |
| 3 | BeiGene, Ltd. (ONC) | 15.5% | 12.7% | |
| 4 | ACADIA Pharmaceuticals Inc. (ACAD) | 4.8% | 5.9% | |
| 5 | BioMarin Pharmaceutical Inc. (BMRN) | 3.3% | 3.4% | |
| 6 | Ascendis Pharma A/S (ASND) | 3.0% | 3.1% | |
| 7 | argenx SE (ARGX) | 1.9% | 2.0% | |
| 8 | BioCryst Pharmaceuticals, Inc. (BCRX) | 0.9% | 1.2% | |
| 9 | Madrigal Pharmaceuticals, Inc. (MDGL) | 0.6% | 0.8% | Entered the top 10 |
| 10 | Kodiak Sciences Inc. (KOD) | 6.1% | 0.7% | |
| — | Mirati Therapeutics, Inc. (MRTX) | 1.0% | 0.7% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).